Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
in institutional, national, and international forums. Create active collaboration with the newly established multidisciplinary California Institute of Immunology and Immunotherapy (CIII), in
-
University of California, Los Angeles | Los Angeles, California | United States | about 20 hours ago
Project Scientist Positions in Hematology-Oncology 2025-2026 Job #JPF10771 Medicine-Hematology-Oncology / David Geffen School Of Medicin / UCLA Position overview Salary range: See Table 37-B [https
-
Center Department: Medicine | School Biomedical Sciences Molecular Medicine and Therapeutics The Yang Lab (https://medicine.osu.edu/find-faculty/non-clinical/molecular-medicine-and-therapeutics/liping-yang
-
change the world. For more information about the department visit http://pathology.stanford.edu About the Lab: The LSRP will work in the lab of Dr. Ansuman Satpathy, MD, PhD (Department of Pathology and
-
change the world. For more information about the department visit: http://pathology.stanford.edu About the Lab: The LSRP will work in the lab of Dr. Ansuman Satpathy, MD, PhD (Department of Pathology and
-
carry out the doctoral thesis for the 26/27 academic year. Adoptive cell therapyagainst cancer is a type of immunotherapy that is based on the use of agents that enhance the immune cells of the patients
-
resources that drive innovative biostatistical and statistical methods. Opportunities for broader impact include initiatives such as the Cancer AI Alliance: https://www.canceralliance.ai . All faculty
-
change the world. For more information about the department visit http://pathology.stanford.edu About the Lab: The LSRP will work in the lab of Dr. Ansuman Satpathy, MD, PhD (Department of Pathology and
-
change the world. For more information about the department visit: http://pathology.stanford.edu About the Lab: The LSRP will work in the lab of Dr. Ansuman Satpathy, MD, PhD (Department of Pathology and
-
aggressive cancers, with no curative treatments currently available. Recent clinical trials investigating immunotherapy with oncolytic viruses (OVs) have shown promising results, although only a subset of